GlassScriptPhysician profile
Yulia Salamatova
NPI 1285138495
$53,153.59
in general payments reported to CMS, 2019-2025
48 companies · $2,533 in 2025
The $2,533 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $114 · 2021: $464 · 2022: $45K · 2023: $2,549 · 2024: $1,931 · 2025: $2,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,435 · Travel and Lodging: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,435.40 |
| Travel and Lodging | $1,577.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,590.40 | 2022-2023 | Vercise |
| Medtronic, INC. | $20,319.54 | 2022-2025 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $639.36 | 2020-2024 | Ultomiris |
| Abbvie INC. | $456.55 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $456.12 | 2023-2025 | Ingrezza |
| Biogen, INC. | $370.04 | 2023-2025 | Vumerity, Tysabri, Avonex |
| Horizon Therapeutics Plc | $336.22 | 2021-2023 | Uplizna |
| Abbott Laboratories | $303.26 | 2023 | Infinity |
| Ucb, INC. | $238.82 | 2023-2025 | Rystiggo, Zilbrysq, Fintepla |
| Genzyme Corporation | $226.46 | 2023-2025 | |
| Pfizer INC. | $212.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.79 | 2019-2021 | |
| Tg Therapeutics, INC. | $185.63 | 2024-2025 | |
| Mdd US Operations, LLC | $167.82 | 2024 | Gocovri |
| Kyowa Kirin, INC. | $144.94 | 2024 | Nourianz |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $141.75 | 2021-2025 | Valtoco |
| Axsome Therapeutics, INC. | $141.05 | 2025 | Sunosi, Symbravo |
| Teva Pharmaceuticals USA, INC. | $137.38 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $124.98 | 2025 | Xcopri |
| Genentech USA, INC. | $123.41 | 2024 | Ocrevus |
| Merz North America, INC. | $115.00 | 2019 | |
| Argenx US, INC. | $113.02 | 2024-2025 | Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $110.60 | 2023-2025 | Crexont, Rytary, Ongentys |
| Amgen INC. | $104.79 | 2024-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $97.98 | 2024-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $94.83 | 2019 | |
| Csl Behring | $85.75 | 2022 | |
| Merz Pharmaceuticals, LLC | $84.29 | 2024-2025 | Inbrija, Ampyra, Xeomin |
| Lilly USA, LLC | $83.70 | 2024-2025 | Kisunla, Emgality |
| Lundbeck LLC | $74.33 | 2024-2025 | Rexulti, Vyepti |
| Catalyst Pharmaceuticals, INC. | $69.35 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $68.00 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $66.87 | 2025 | Purified Cortrophin Gel |
| Ipsen Biopharmaceuticals, INC | $62.02 | 2025 | Dysport |
| Vanda Pharmaceuticals INC. | $60.81 | 2024-2025 | Ponvory |
| Acadia Pharmaceuticals INC | $57.30 | 2024-2025 | Nuplazid |
| Eisai INC. | $44.65 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $44.11 | 2025 | Wainua |
| Emd Serono, INC. | $42.23 | 2024 | |
| Celgene Corporation | $26.53 | 2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $24.67 | 2024 | Acthar |
| Alnylam Pharmaceuticals INC. | $21.03 | 2025 | Amvuttra |
| Cycle Pharmaceuticals INC | $20.52 | 2024 | Tascenso Odt |
| Janssen Biotech, INC. | $20.42 | 2025 | |
| Livanova USA, INC. | $20.07 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Harmony Biosciences LLC | $19.69 | 2025 | |
| Tanabe Pharma America, INC. | $15.70 | 2025 | Radicava |
| Impel Pharmaceuticals LLC | $3.13 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yulia Salamatova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.